Nashua, N.H.-based iCAD, Inc. and Solis Mammography, a U.S. provider of mammography and breast health services, announce a five-year partnership whereby iCAD will provide Solis Mammography’s nationwide network with its latest artificial intelligence (AI) breast health solutions, including ProFound AI for DBT and ProFound AI Risk, a clinical decision support tool to provide a two-year breast cancer risk estimation based on a screening mammogram.
“After a thorough evaluation of all available AI solutions, we have chosen iCAD’s ProFound AI platform as our sole breast health AI solution to integrate with our Hologic 3D mammography systems throughout our entire network,” says Grant Davies, president and CEO of Solis Mammography. “ProFound AI will further enhance patient care and outcomes for the over one million women we serve while also supporting our continued growth and expansion.”
ProFound AI for DBT is a workflow solution trained with the latest in deep-learning AI capabilities. It assists radiologists by analyzing each individual DBT image to identify potentially malignant lesions. Moreover, the ProFound AI platform powered by Panorama is compatible with all leading mammography systems and allows for integration with major PACS for decision-support capabilities across large networks.
“Our partnership with Solis underscores our ongoing commitment to improving women’s health and we are thrilled that even more women across the United States will benefit from our revolutionary technology that is helping to improve lives,” says Michael Klein, chairman and CEO of iCAD. “ProFound AI powered by Panorama offers unparalleled benefits to patients and radiologists alike, including a clinically proven improvement in sensitivity and specificity, which dramatically improves reading accuracy for mammograms and reduces the rate of false positives.
“Likewise, with the addition of our recently introduced ProFound AI Risk offering, we believe we will move mammography from what is today an age-based screening paradigm to a risk-adjusted precision screening paradigm that is personalized for every woman,” Klein adds.
In September, research published in the peer-reviewed journal Radiology concluded that the ProFound AI Risk model is effective in identifying women at a high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening.
“The recent adoption of ProFound AI for DBT throughout our network will allow our radiologists to quickly and accurately evaluate their patients’ 3D mammography images and aid in the identification of suspicious lesions earlier,” says Alexander Sardiña, MD, chief medical officer at Solis Mammography. “In addition, the ability to provide a short-term, two-year breast cancer risk assessment will significantly enhance clinical decision making and further complement the armamentarium of breast cancer diagnostic and therapeutic tools available at Solis Mammography.”